PL4104687T3 - Kompozycje i sposoby syntezy cząsteczek rna z kapem 5' - Google Patents

Kompozycje i sposoby syntezy cząsteczek rna z kapem 5'

Info

Publication number
PL4104687T3
PL4104687T3 PL22175377.5T PL22175377T PL4104687T3 PL 4104687 T3 PL4104687 T3 PL 4104687T3 PL 22175377 T PL22175377 T PL 22175377T PL 4104687 T3 PL4104687 T3 PL 4104687T3
Authority
PL
Poland
Prior art keywords
synthesizing
compositions
methods
capped rnas
rnas
Prior art date
Application number
PL22175377.5T
Other languages
English (en)
Inventor
Richard I. Hogrefe
Alexandre Lebedev
Anton P. Mccaffrey
Dongwon Shin
Original Assignee
Trilink Biotechnologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4104687(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trilink Biotechnologies, Llc filed Critical Trilink Biotechnologies, Llc
Publication of PL4104687T3 publication Critical patent/PL4104687T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL22175377.5T 2015-09-21 2016-09-20 Kompozycje i sposoby syntezy cząsteczek rna z kapem 5' PL4104687T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562221248P 2015-09-21 2015-09-21

Publications (1)

Publication Number Publication Date
PL4104687T3 true PL4104687T3 (pl) 2024-05-27

Family

ID=58387109

Family Applications (5)

Application Number Title Priority Date Filing Date
PL16849423T PL3352584T3 (pl) 2015-09-21 2016-09-20 Kompozycje i sposoby do syntezy rna z kapem 5’
PL21173278.9T PL3906789T3 (pl) 2015-09-21 2016-09-20 Inicjujące startery oligonukleotydowe z kapem do syntezy cząsteczek rna z kapem 5'
PL22190426.1T PL4140491T3 (pl) 2015-09-21 2016-09-20 Sposoby syntezy rna z kapem 5'
PL22175377.5T PL4104687T3 (pl) 2015-09-21 2016-09-20 Kompozycje i sposoby syntezy cząsteczek rna z kapem 5'
PL21173142.7T PL3954225T3 (pl) 2015-09-21 2016-09-20 Inicjujące startery oligonukleotydowe z kapem do syntezy cząsteczek rna z kapem 5'

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL16849423T PL3352584T3 (pl) 2015-09-21 2016-09-20 Kompozycje i sposoby do syntezy rna z kapem 5’
PL21173278.9T PL3906789T3 (pl) 2015-09-21 2016-09-20 Inicjujące startery oligonukleotydowe z kapem do syntezy cząsteczek rna z kapem 5'
PL22190426.1T PL4140491T3 (pl) 2015-09-21 2016-09-20 Sposoby syntezy rna z kapem 5'

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21173142.7T PL3954225T3 (pl) 2015-09-21 2016-09-20 Inicjujące startery oligonukleotydowe z kapem do syntezy cząsteczek rna z kapem 5'

Country Status (21)

Country Link
US (9) US10913768B2 (pl)
EP (8) EP4424835B1 (pl)
JP (4) JP6814997B2 (pl)
KR (3) KR102500198B1 (pl)
CN (8) CN108366604A (pl)
AU (5) AU2016328645C1 (pl)
CA (2) CA3218662A1 (pl)
CY (1) CY1124306T1 (pl)
DK (5) DK3906789T5 (pl)
ES (5) ES2968391T3 (pl)
FI (4) FI4104687T3 (pl)
HK (1) HK1255236A1 (pl)
HR (1) HRP20211091T1 (pl)
HU (5) HUE064227T2 (pl)
LT (6) LT4104687T (pl)
PL (5) PL3352584T3 (pl)
PT (6) PT4140491T (pl)
RS (1) RS62129B1 (pl)
SI (5) SI3352584T1 (pl)
SM (1) SMT202100396T1 (pl)
WO (1) WO2017053297A1 (pl)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
FI4104687T3 (fi) 2015-09-21 2024-03-01 Trilink Biotechnologies Llc Koostumuksia ja menetelmiä 5-huputettujen RNA:iden syntetisoimiseksi
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP4163374A1 (en) 2015-11-23 2023-04-12 The Regents of the University of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
EP3529255A1 (en) 2016-10-19 2019-08-28 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
KR102842382B1 (ko) 2017-03-24 2025-08-04 큐어백 에스이 Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
KR102773542B1 (ko) * 2017-06-30 2025-02-25 코덱시스, 인코포레이티드 T7 rna 폴리머라제 변이체
CA3066767A1 (en) 2017-06-30 2019-01-03 Codexis, Inc. T7 rna polymerase variants
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
ES2983060T3 (es) * 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
KR20250093420A (ko) 2017-09-29 2025-06-24 인텔리아 테라퓨틱스, 인크. 게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
MX2020003608A (es) 2017-09-29 2020-09-25 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr.
EP3765477A1 (en) * 2018-03-15 2021-01-20 BioNTech RNA Pharmaceuticals GmbH 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
SG11202008225PA (en) 2018-04-17 2020-11-27 Curevac Ag Novel rsv rna molecules and compositions for vaccination
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
US12371646B2 (en) 2018-06-28 2025-07-29 CureVac Manufacturing GmbH Bioreactor for RNA in vitro transcription
CA3122080A1 (en) 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
CN113396219A (zh) 2019-02-11 2021-09-14 埃泽瑞斯公司 通过切向流过滤纯化mRNA
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
MX2021011690A (es) 2019-03-28 2022-01-06 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
MA55527A (fr) 2019-03-28 2022-02-09 Intellia Therapeutics Inc Polynucléotides, compositions et procédés d'expression de polypeptides
CA3134271A1 (en) 2019-03-28 2020-10-01 Intellia Therapeutics, Inc. Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control
US20220362360A1 (en) * 2019-04-26 2022-11-17 Etherna Immunotherapies Nv Mrna formulation
US20220220189A1 (en) * 2019-05-24 2022-07-14 Ultragenyx Pharmaceutical Inc. Compositions and methods for treatment of hemochromatosis
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
EP4003508A1 (en) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
JP2022544412A (ja) 2019-08-14 2022-10-18 キュアバック アーゲー 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
EP4076647A1 (en) 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP7793525B2 (ja) 2020-02-04 2026-01-05 キュアバック エスイー コロナウイルスワクチン
PL248416B1 (pl) * 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
JP7602807B2 (ja) * 2020-02-28 2024-12-19 国立研究開発法人科学技術振興機構 キャップ化ｒｎａの製造方法
CN113151312B (zh) * 2020-03-02 2022-12-09 中国科学院微生物研究所 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用
WO2021178510A1 (en) 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE Rna compositions targeting claudin-18.2
CA3173803A1 (en) 2020-04-21 2021-10-28 Karin Jooss Capping compounds, compositions and methods of use thereof
US11547673B1 (en) * 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
EP4143217A4 (en) 2020-05-01 2024-10-02 Arcturus Therapeutics, Inc. NUCLEIC ACIDS AND METHODS FOR TREATING CYSTIC FIBROSIS
JP2023526090A (ja) 2020-05-19 2023-06-20 ハドソン インスティチュート オブ メディカル リサーチ オリゴヌクレオチド
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
KR20230034333A (ko) * 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
CN113416763A (zh) * 2020-08-20 2021-09-21 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
EP4208286A1 (en) 2020-09-01 2023-07-12 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
KR102366490B1 (ko) 2020-10-20 2022-02-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
CN116547077A (zh) 2020-11-27 2023-08-04 库瑞瓦格Rna打印机有限公司 用于通过毛细管聚合酶链式反应制备dna产物的设备
CA3201552A1 (en) 2020-12-09 2022-06-16 Thomas ZIEGENHALS Rna manufacturing
KR20230129996A (ko) 2020-12-11 2023-09-11 인텔리아 테라퓨틱스, 인크. 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
JP2024501022A (ja) 2020-12-28 2024-01-10 アークトゥルス セラピューティクス， インコーポレイテッド Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ）
EP4087938A2 (en) 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
EP4294445A1 (en) 2021-02-19 2023-12-27 Pfizer Inc. Methods of protecting rna
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
KR20220140140A (ko) 2021-04-09 2022-10-18 한미정밀화학주식회사 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
KR20240038705A (ko) 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
JPWO2023282245A1 (pl) 2021-07-05 2023-01-12
EP4116313A1 (en) 2021-07-07 2023-01-11 Westfälische Wilhelms-Universität Münster Cap analog for the 5'-end of eukaryotic messenger rnas
TW202320842A (zh) 2021-07-29 2023-06-01 德商拜恩技術股份公司 用於治療黑色素瘤之組合物及方法
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
WO2023007019A1 (en) 2021-07-30 2023-02-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN113603739B (zh) 2021-08-27 2024-08-23 上海兆维科技发展有限公司 一种加帽类似物及其应用
JP2024534871A (ja) * 2021-08-31 2024-09-26 ハンミ・ファイン・ケミカル・カンパニー・リミテッド ｍＲＮＡキャップ類似体及びその用途
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CN113957108B (zh) * 2021-09-09 2025-01-10 上海兆维科技发展有限公司 一种加帽rna的合成方法以及加帽rna转录反应液
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
US20240425541A1 (en) 2021-10-22 2024-12-26 BioNTech SE Oligosaccharide compounds and complexes
EP4401788A1 (en) 2021-10-22 2024-07-24 BioNTech SE Oligosaccharide complexes and uses
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4402150A1 (en) 2021-10-22 2024-07-24 BioNTech SE Oligosaccharide compounds and complexes
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
WO2023067123A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4402149A1 (en) 2021-10-22 2024-07-24 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
AU2022382975A1 (en) 2021-11-03 2024-05-02 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20230083197A (ko) 2021-12-01 2023-06-09 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
WO2023115495A1 (zh) * 2021-12-23 2023-06-29 北京毅新博创生物科技有限公司 质谱法检测mRNA加帽效率的方法
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250099588A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
KR20230123318A (ko) 2022-02-16 2023-08-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
GB2615784A (en) 2022-02-18 2023-08-23 Phion Therapeutics Ltd mRNA vaccine
EP4261217A4 (en) 2022-02-28 2024-09-11 Guangzhou Henovcom Bioscience Co., Ltd. Compound for rna capping and application of compound
CN115260264B (zh) 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
JP2025507751A (ja) 2022-03-01 2025-03-21 クリスパー・セラピューティクス・アクチェンゲゼルシャフト アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物
JP2025507894A (ja) * 2022-03-01 2025-03-21 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物及び方法
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
US12522630B2 (en) 2022-03-31 2026-01-13 Hanmi Fine Chemical Co., Ltd. MRNA cap analog and uses thereof
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
GB2618818A (en) 2022-05-18 2023-11-22 Phion Therapeutics Ltd Vaccine
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
US20250215043A1 (en) * 2022-05-31 2025-07-03 Nutcracker Therapeutics, Inc. Rna cap analogs and methods of use
WO2023235422A2 (en) * 2022-05-31 2023-12-07 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
TW202408595A (zh) 2022-06-16 2024-03-01 美商英特利亞醫療公司 用於對細胞進行遺傳修飾之方法及組合物
CN115109110B (zh) * 2022-06-22 2024-07-12 江苏申基生物科技有限公司 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用
CN114853836B (zh) * 2022-06-24 2024-05-14 江苏申基生物科技有限公司 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115057903B (zh) * 2022-06-22 2024-03-29 江苏申基生物科技有限公司 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用
WO2023246860A1 (zh) * 2022-06-22 2023-12-28 江苏申基生物科技有限公司 一种起始加帽寡核苷酸引物及其制备方法和应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN114941018B (zh) * 2022-06-28 2023-09-22 翌圣生物科技(上海)股份有限公司 cap1帽类似物的合成方法
KR20240010238A (ko) 2022-07-15 2024-01-23 한미정밀화학주식회사 캡 유사체 및 이의 용도
WO2024017375A1 (zh) * 2022-07-22 2024-01-25 广州市恒诺康医药科技有限公司 用于rna加帽的环状取代化合物及其应用
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA
CN115925773A (zh) * 2022-08-23 2023-04-07 合肥华纳生物医药科技有限公司 一种新型信使核糖核酸帽类似物
EP4577553A2 (en) * 2022-08-26 2025-07-02 TriLink BioTechnologies, LLC Efficient method for making highly purified 5'-capped oligonucleotides
WO2024051696A1 (zh) * 2022-09-05 2024-03-14 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
JP2025531877A (ja) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025532191A (ja) 2022-09-26 2025-09-29 ビオンテック・ソシエタス・エウロパエア 核酸複合体及びその使用
JP2025532686A (ja) 2022-09-26 2025-10-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
IL319682A (en) 2022-10-06 2025-05-01 BioNTech SE RNA complexes targeting claudin-18.2
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4605010A1 (en) 2022-10-21 2025-08-27 BioNTech SE Nucleic acid complexes and uses thereof
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
CN116143855B (zh) * 2022-11-08 2023-11-28 江苏申基生物科技有限公司 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
TW202428878A (zh) 2022-12-23 2024-07-16 美商英特利亞醫療公司 用於基因體編輯之系統及方法
EP4397669A1 (en) 2023-01-06 2024-07-10 Westfälische Wilhelms-Universität Münster Photocaged cap analogs for the 5'-end of rnas
JP2026501855A (ja) 2023-01-20 2026-01-16 アストラゼネカ・アクチエボラーグ ワクチン
JP2026501863A (ja) 2023-01-20 2026-01-16 アストラゼネカ・アクチエボラーグ 核酸分子
WO2024160895A1 (en) 2023-01-31 2024-08-08 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
KR20250157528A (ko) 2023-03-03 2025-11-04 나티아스 인크. 폴리인산화 뉴클레오시드, 폴리인산화 뉴클레오시드의 합성에 사용되는 인산부 활성화 뉴클레오티드 및 그 합성 방법, 및 인산부 활성화 뉴클레오티드를 사용한 폴리인산화 뉴클레오시드의 합성 방법
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN116356002A (zh) * 2023-03-28 2023-06-30 四川康德赛医疗科技有限公司 一种rna加帽效率的定量方法、试剂盒及其应用
TW202444914A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 抑制子融合蛋白系統
AU2024248139A1 (en) 2023-03-29 2025-09-25 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
CN118726510A (zh) * 2023-03-31 2024-10-01 苏州近岸蛋白质科技股份有限公司 一管法酶促合成加帽mRNA的方法
CN118772219B (zh) * 2023-04-04 2025-12-02 深圳瑞吉生物科技有限公司 一种用于核酸的5’端加帽的含卤化合物及其应用
EP4701657A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
EP4701658A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN121605199A (zh) 2023-05-16 2026-03-03 科威瓦克制造有限公司 使用dna珠粒的改进的rna的体外转录
WO2024245907A1 (en) 2023-05-26 2024-12-05 CureVac SE Cancer antigens
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025006851A1 (en) 2023-06-29 2025-01-02 Nutcracker Therapeutics, Inc. Ethyl modified rna caps and methods of use
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
TW202526022A (zh) * 2023-09-06 2025-07-01 美商垂林克生物技術有限責任公司 帽類似物及其使用方法
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025071359A1 (ko) 2023-09-27 2025-04-03 한미정밀화학 주식회사 mRNA 캡 유사체 및 이의 용도
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
TW202540417A (zh) 2023-11-10 2025-10-16 美商英特利亞醫療公司 用於基因體編輯之組合物、方法及系統
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease
WO2025137301A1 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Methods for rapid engineering of cells
TW202525287A (zh) 2023-12-21 2025-07-01 德商拜恩技術運輸科技有限責任公司 可離子化脂質
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
CN117534719B (zh) 2024-01-09 2024-05-14 北京悦康科创医药科技股份有限公司 一种c6'取代锁核酸修饰加帽类似物及其应用
WO2025181704A2 (en) 2024-02-27 2025-09-04 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025208142A2 (en) 2024-03-29 2025-10-02 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
EP4650358A3 (en) * 2024-04-26 2026-01-14 Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Ribose-modified cap analog and use thereof
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
WO2025264662A1 (en) 2024-06-18 2025-12-26 BioNTech SE Compositions and methods for treatment of melanoma
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
WO2026033380A1 (en) 2024-08-05 2026-02-12 BioNTech SE Process for preparing oligosaccharide complexes
CN120608113A (zh) * 2024-11-29 2025-09-09 上海蓝鹊生物医药有限公司 一种合成Cap2结构5'-加帽RNA的组合和方法
CN119306779A (zh) * 2024-12-13 2025-01-14 上海科泽永欣生物科技有限公司 一种含r构型的起始加帽寡核苷酸引物及其合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1997A (en) 1841-03-03 Improvement in the mode of rendering fabrics water-proof
EP0081099A3 (en) * 1981-12-04 1983-08-10 Sloan-Kettering Institute For Cancer Research Capped oligonucleotide anti-viral agents
DE3148702C2 (de) * 1981-12-09 1985-05-15 Dieter Gräßlin Feinwerktechnik, 7742 St Georgen Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte
US5837852A (en) 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
WO2000056749A1 (en) 1999-03-24 2000-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7629325B2 (en) * 2004-10-11 2009-12-08 Technion Research & Development Foundation Ltd. Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy
AU2005313883B2 (en) 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
WO2007139723A1 (en) 2006-06-01 2007-12-06 Trilink Biotechnologies Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
US20080248469A1 (en) 2006-08-16 2008-10-09 Applera Corporation Methods for Identifying Nucleotides of Interest in Target Polynucleotides
DK2167523T3 (da) 2007-06-19 2014-09-08 Univ Louisiana State Syntese og anvendelse af anti-reverse phosphorothioatanaloger af messenger-rna-cappen
WO2009058911A2 (en) * 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
US8557972B2 (en) 2009-12-21 2013-10-15 University Of Washington Through Its Center For Commercialization Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA
WO2011157617A1 (en) 2010-06-17 2011-12-22 Febit Holding Gmbh Complex set of mirna libraries
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
EP2834259A4 (en) * 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
JP2016515216A (ja) 2013-03-14 2016-05-26 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーｒｎａのキャップ効率の定量的評価
JP6148592B2 (ja) 2013-10-15 2017-06-14 ヤマハ発動機株式会社 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両
WO2016098028A1 (en) 2014-12-16 2016-06-23 Novartis Ag End capped nucleic acid molecules
FI4104687T3 (fi) 2015-09-21 2024-03-01 Trilink Biotechnologies Llc Koostumuksia ja menetelmiä 5-huputettujen RNA:iden syntetisoimiseksi
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP3529255A1 (en) 2016-10-19 2019-08-28 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
EP3765477A1 (en) 2018-03-15 2021-01-20 BioNTech RNA Pharmaceuticals GmbH 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
PL248416B1 (pl) 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432884A1 (pl) 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
US11547673B1 (en) 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
KR20230034333A (ko) 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
KR102366490B1 (ko) 2020-10-20 2022-02-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드

Also Published As

Publication number Publication date
CN117025590A (zh) 2023-11-10
PT4104687T (pt) 2024-02-27
PT3954225T (pt) 2024-01-02
LT3352584T (lt) 2021-08-10
CN113584020A (zh) 2021-11-02
DK4104687T3 (da) 2024-03-04
US20180273576A1 (en) 2018-09-27
EP4424835A3 (en) 2024-10-23
EP3954224A1 (en) 2022-02-16
US11578095B2 (en) 2023-02-14
DK3906789T3 (da) 2024-01-08
ES2964690T3 (es) 2024-04-09
AU2021206780C1 (en) 2024-01-04
KR102500198B1 (ko) 2023-02-16
JP2018527015A (ja) 2018-09-20
KR20240095306A (ko) 2024-06-25
HK1255236A1 (zh) 2019-08-09
EP4104687A1 (en) 2022-12-21
PT3906789T (pt) 2023-12-18
US12103944B2 (en) 2024-10-01
US11878991B2 (en) 2024-01-23
CA2999274A1 (en) 2017-03-30
LT3954225T (lt) 2024-02-12
SI4104687T1 (sl) 2024-03-29
DK3352584T3 (da) 2021-07-12
SMT202100396T1 (it) 2021-09-14
FI3906789T3 (fi) 2024-01-11
RS62129B1 (sr) 2021-08-31
EP3352584B1 (en) 2021-05-12
CY1124306T1 (el) 2022-07-22
AU2021206780A1 (en) 2021-08-12
US20220289786A1 (en) 2022-09-15
FI4104687T3 (fi) 2024-03-01
EP3954225A1 (en) 2022-02-16
PL3352584T3 (pl) 2021-11-08
JP6814997B2 (ja) 2021-01-20
PL4140491T3 (pl) 2024-02-26
WO2017053297A1 (en) 2017-03-30
SI3352584T1 (sl) 2021-09-30
US20210371452A1 (en) 2021-12-02
CN121085982A (zh) 2025-12-09
US11414453B2 (en) 2022-08-16
DK4140491T5 (da) 2024-07-22
HUE065203T2 (hu) 2024-05-28
SI3906789T1 (sl) 2024-03-29
ES2968391T3 (es) 2024-05-09
CN116751827B (zh) 2024-01-30
ES2879686T3 (es) 2021-11-22
JP7082174B2 (ja) 2022-06-07
EP4276189A3 (en) 2024-01-17
CN120842296A (zh) 2025-10-28
EP3906789A1 (en) 2021-11-10
ES2972098T3 (es) 2024-06-11
EP3954225B1 (en) 2023-11-22
HUE064227T2 (hu) 2024-02-28
US20190144490A1 (en) 2019-05-16
EP3352584A4 (en) 2019-03-27
EP3906789B1 (en) 2023-11-22
CA3218662A1 (en) 2017-03-30
AU2023201915A1 (en) 2023-05-04
CN108366604A (zh) 2018-08-03
US10494399B2 (en) 2019-12-03
AU2016328645A1 (en) 2018-04-19
EP4276189A2 (en) 2023-11-15
US20210261597A1 (en) 2021-08-26
LT4104687T (lt) 2024-02-26
JP2022109973A (ja) 2022-07-28
AU2023229522B2 (en) 2025-02-20
PT3352584T (pt) 2021-07-13
US20190270766A1 (en) 2019-09-05
AU2016328645B2 (en) 2021-05-13
AU2021206780B2 (en) 2023-04-06
EP3352584A1 (en) 2018-08-01
EP4104687B1 (en) 2024-01-31
JP2021048864A (ja) 2021-04-01
CN116751827A (zh) 2023-09-15
US20240140982A1 (en) 2024-05-02
HUE055458T2 (hu) 2021-11-29
JP2024150459A (ja) 2024-10-23
DK4140491T3 (da) 2023-11-27
EP4140491A1 (en) 2023-03-01
KR20180050409A (ko) 2018-05-14
CA2999274C (en) 2023-12-19
LT3906789T (lt) 2024-02-12
DK3954225T3 (da) 2024-01-02
HUE065704T2 (hu) 2024-06-28
LT4424835T (lt) 2026-03-10
SI4140491T1 (sl) 2024-01-31
AU2023229522A1 (en) 2023-09-28
ES2968335T3 (es) 2024-05-09
KR20230026535A (ko) 2023-02-24
JP7594563B2 (ja) 2024-12-04
US20240158433A1 (en) 2024-05-16
US20250171489A1 (en) 2025-05-29
CN116590285A (zh) 2023-08-15
EP4424835A2 (en) 2024-09-04
PT4140491T (pt) 2023-12-05
CN121064267A (zh) 2025-12-05
EP4140491B1 (en) 2023-09-13
EP4424835B1 (en) 2026-01-21
HRP20211091T1 (hr) 2021-10-15
US10913768B2 (en) 2021-02-09
PL3954225T3 (pl) 2024-05-20
AU2016328645C1 (en) 2021-10-28
FI4140491T3 (fi) 2023-11-20
DK3954225T5 (da) 2024-08-05
DK3906789T5 (da) 2024-08-05
KR102670937B1 (ko) 2024-05-31
US10519189B2 (en) 2019-12-31
AU2023201915B2 (en) 2024-07-25
PL3906789T3 (pl) 2024-05-20
LT4140491T (lt) 2023-11-10
AU2025203425A1 (en) 2025-05-29
SI3954225T1 (sl) 2024-03-29
US12258369B2 (en) 2025-03-25
HUE065331T2 (hu) 2024-05-28
DK4104687T5 (da) 2024-07-22
PT4424835T (pt) 2026-02-25
FI3954225T3 (fi) 2023-12-28

Similar Documents

Publication Publication Date Title
LT4104687T (lt) Kompozicijos ir būdai, skirti 5'-kepurę turinčių rnr sintetinimui
IL259576A (en) Preparations and methods for immuno-oncology
GB2546350B (en) Compositions and methods
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
SG10201609929QA (en) Etching compositions and methods for using same
IL249982A0 (en) Oligosaccharide compounds and methods of producing them
IL260124A (en) Compounds and methods for reducing tau expression
GB201718801D0 (en) Compositions and methods for inhibiting factor D
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL258292A (en) Methods and compositions for reducing metastases
IL246879A0 (en) Preparations of Epilimod and methods of using them
IL274524A (en) Preparations and methods for aquaculture
GB201520255D0 (en) Composition and method
GB2550632B (en) Compositions and uses and methods relating thereto
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
GB201502983D0 (en) Composition and process
ZA201704942B (en) Compositions for improving budbreak and flowering
GB201512996D0 (en) Compositions and methods
GB201509420D0 (en) Composition and method
GB201514413D0 (en) Compositions and methods
GB201513492D0 (en) Method and composition
IL256261B (en) Hide1 compositions and methods
GB201522554D0 (en) Methods and compositions
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods